Stefaan Verhulst
Overview
Explore the profile of Stefaan Verhulst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1072
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Merens V, Knetemann E, Gurbuz E, De Smet V, Messaoudi N, Reynaert H, et al.
JHEP Rep
. 2025 Jan;
7(1):101223.
PMID: 39758511
Background & Aims: The progression of chronic liver disease (CLD) is characterized by excessive extracellular matrix deposition, disrupting hepatic architecture and function. Upon liver injury, hepatic stellate cells (HSCs) differentiate...
2.
Krivec N, Couvreu de Deckersberg E, Lei Y, Al Delbany D, Regin M, Verhulst S, et al.
Cell Death Dis
. 2024 Nov;
15(11):852.
PMID: 39572522
Gain of 1q is a highly recurrent chromosomal abnormality in human pluripotent stem cells. In this work, we show that gains of 1q impact the differentiation capacity to derivates of...
3.
Muturi H, Ghadieh H, Asalla S, Lester S, Belew G, Zaidi S, et al.
Mol Metab
. 2024 Aug;
88:102010.
PMID: 39168268
Objectives: Hepatic CEACAM1 expression declines with advanced hepatic fibrosis stage in patients with metabolic dysfunction-associated steatohepatitis (MASH). Global and hepatocyte-specific deletions of Ceacam1 impair insulin clearance to cause hepatic insulin...
4.
Cools L, Dastjerd M, Smout A, Merens V, Yang Y, Reynaert H, et al.
Biofabrication
. 2024 Jun;
16(3).
PMID: 38865994
The lack of adequate humanmodels that recapitulate the cellular composition and response of the human liver to injury hampers the development of anti-fibrotic drugs. The goal of this study was...
5.
De Smet V, Gurbuz E, Eysackers N, Dewyse L, Smout A, Dastjerd M, et al.
JHEP Rep
. 2024 May;
6(5):101036.
PMID: 38694958
Background & Aims: Chronic liver disease (CLD) remains a global health issue associated with a significant disease burden. Liver fibrosis, a hallmark of CLD, is characterised by the activation of...
6.
Muturi H, Ghadieh H, Asalla S, Lester S, Verhulst S, Stankus H, et al.
bioRxiv
. 2024 Apr;
PMID: 38617330
Objectives: Hepatic CEACAM1 expression declines with advanced hepatic fibrosis stage in patients with MASH. Global and hepatocyte-specific deletions of impair insulin clearance to cause hepatic insulin resistance and steatosis. They...
7.
Chai Y, To S, Simorgh S, Zaunz S, Zhu Y, Ahuja K, et al.
Adv Sci (Weinh)
. 2023 Dec;
11(5):e2304421.
PMID: 38037510
Although human pluripotent stem cell (PSC)-derived brain organoids have enabled researchers to gain insight into human brain development and disease, these organoids contain solely ectodermal cells and are not vascularized...
8.
Muturi H, Ghadieh H, Abdolahipour R, Stankus H, Belew G, Liu J, et al.
Metabolism
. 2023 Apr;
144:155562.
PMID: 37088122
Objectives: Hepatocytic CEACAM1 plays a critical role in NASH pathogenesis, as bolstered by the development of insulin resistance, visceral obesity, steatohepatitis and fibrosis in mice with global Ceacam1 (Cc1) deletion....
9.
Thienpont A, Verhulst S, van Grunsven L, Rogiers V, Vanhaecke T, Mertens B
ALTEX
. 2022 Nov;
40(2):271-286.
PMID: 36343114
Transcriptomics-based biomarkers are promising new approach methodologies (NAMs) to identify molecular events underlying the genotoxic mode of action of chemicals. Previously, we developed the GENOMARK biomarker, consisting of 84 genes...
10.
van Os E, Cools L, Eysackers N, Szafranska K, Smout A, Verhulst S, et al.
Biomaterials
. 2022 Oct;
290:121817.
PMID: 36208587
Chronic liver disease can lead to liver fibrosis and ultimately cirrhosis, which is a significant health burden and a major cause of death worldwide. Reliable in vitro models are lacking...